For the readers interested in the stock health of Pieris Pharmaceuticals Inc. (PIRS). It is currently valued at $0.94. When the transactions were called off in the previous session, Stock hit the highs of $0.98, after setting-off with the price of $0.96. Company’s stock value dipped to $0.9304 during the trading on the day. When the trading was stopped its value was $0.96.Recently in News on November 9, 2022, Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT. A webcast of the company’s presentation will be available at this link. You can read further details here
Pieris Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.0755 on 01/04/22, with the lowest value was $0.9244 for the same time period, recorded on 11/21/22.
Pieris Pharmaceuticals Inc. (PIRS) full year performance was -73.42%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Pieris Pharmaceuticals Inc. shares are logging -76.91% during the 52-week period from high price, and 1.81% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.92 and $4.08.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4307414 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Pieris Pharmaceuticals Inc. (PIRS) recorded performance in the market was -75.10%, having the revenues showcasing -40.44% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 71.50M, as it employees total of 124 workers.
Market experts do have their say about Pieris Pharmaceuticals Inc. (PIRS)
During the last month, 0 analysts gave the Pieris Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.3925, with a change in the price was noted -1.06. In a similar fashion, Pieris Pharmaceuticals Inc. posted a movement of -52.94% for the period of last 100 days, recording 223,456 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PIRS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Pieris Pharmaceuticals Inc. (PIRS)
Raw Stochastic average of Pieris Pharmaceuticals Inc. in the period of last 50 days is set at 3.06%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 7.40%. In the last 20 days, the company’s Stochastic %K was 7.85% and its Stochastic %D was recorded 10.40%.
Bearing in mind the latest performance of Pieris Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -75.10%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -43.31%, alongside a downfall of -73.42% for the period of the last 12 months. The shares increased approximately by -3.51% in the 7-day charts and went up by -6.82% in the period of the last 30 days. Common stock shares were lifted by -40.44% during last recorded quarter.